SEP 07, 2016 1:30 PM PDT

Manipulating the Microbiome to Prevent and Treat Infection

Speakers
  • Professor of Internal Medicine and Pathology, University of Iowa
    Biography
      Dr. Diekema is a Professor of Internal Medicine and Pathology at the University of Iowa Carver College of Medicine. After graduating from Vanderbilt University School of Medicine, Dr. Diekema did an internal medicine residency at the University of Virginia, and completed fellowships in infectious diseases, hospital epidemiology and medical microbiology at the University of Iowa, where he also received an MS in Preventive Medicine.
      Dr. Diekema currently serves as director of the Division of Infectious Diseases at the University of Iowa Carver College of Medicine, associate director of the University of Iowa Hospital Clinical Microbiology Laboratory, the associate hospital epidemiologist at University of Iowa Healthcare.
      Dr. Diekema's clinical and research interests include several aspects of healthcare epidemiology, including the epidemiology of invasive fungal infections in hospitalized patients, and the epidemiology of antimicrobial resistance. He has served on national committees that establish standards in clinical microbiology and infection prevention, including the Clinical and Laboratory Standards Institute (CLSI) and the CDC's Healthcare Infection Control Practices Advisory Committee (HICPAC), of which he is currently co-chair. He is also the immediate past-president of the Society for Healthcare Epidemiology of America (SHEA).

    Abstract:

    Healthcare associated infections can be a consequence of a microbiome alteration. Increasingly, treatment and prevention strategies focus on manipulating host microbiota, the two most common examples being (1) suppression of certain skin and mucosal microbiota, and (2) preservation or restoration of intestinal microbial communities.

    After this presentation, participants should be able to:  

    (a) discuss the evidence in support of chlorhexidine application to the skin and oropharynx of hospitalized patients to prevent infection
    (b) implement interventions to reduce the likelihood of Clostridium difficile recurrence after host exposure to antimicrobial agents.
     


    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    Loading Comments...
    Show Resources